Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Evaluating the prognostic potential of the Ki67 index and tumor infiltrating lymphocytes in olfactory neuroblastoma.

Classe M, Burgess A, El Zein S, Wassef M, Herman P, Mortuaire G, Leroy X, Malouf GG, Verillaud B.

Histopathology. 2019 Jul 15. doi: 10.1111/his.13954. [Epub ahead of print]

PMID:
31306501
2.

Long non-coding RNAs in genitourinary malignancies: a whole new world.

Flippot R, Beinse G, Boilève A, Vibert J, Malouf GG.

Nat Rev Urol. 2019 May 20. doi: 10.1038/s41585-019-0195-1. [Epub ahead of print] Review.

PMID:
31110275
3.

Dynamic Evolution of Clonal Composition and Neoantigen Landscape in Recurrent Metastatic Melanoma with a Rare Combination of Driver Mutations.

Davidson G, Coassolo S, Kieny A, Ennen M, Pencreach E, Malouf GG, Lipsker D, Davidson I.

J Invest Dermatol. 2019 Feb 15. pii: S0022-202X(19)30108-3. doi: 10.1016/j.jid.2019.01.027. [Epub ahead of print]

PMID:
30776432
4.

p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors.

Carugo A, Minelli R, Sapio L, Soeung M, Carbone F, Robinson FS, Tepper J, Chen Z, Lovisa S, Svelto M, Amin S, Srinivasan S, Del Poggetto E, Loponte S, Puca F, Dey P, Malouf GG, Su X, Li L, Lopez-Terrada D, Rakheja D, Lazar AJ, Netto GJ, Rao P, Sgambato A, Maitra A, Tripathi DN, Walker CL, Karam JA, Heffernan TP, Viale A, Roberts CWM, Msaouel P, Tannir NM, Draetta GF, Genovese G.

Cancer Cell. 2019 Feb 11;35(2):204-220.e9. doi: 10.1016/j.ccell.2019.01.006.

PMID:
30753823
5.

Brain Metastases and Place of Antiangiogenic Therapies in Alveolar Soft Part Sarcoma: A Retrospective Analysis of the French Sarcoma Group.

Malouf GG, Beinse G, Adam J, Mir O, Chamseddine AN, Terrier P, Honore C, Spano JP, Italiano A, Kurtz JE, Coindre JM, Blay JY, Le Cesne A.

Oncologist. 2019 Jan 9. pii: theoncologist.2018-0074. doi: 10.1634/theoncologist.2018-0074. [Epub ahead of print]

PMID:
30626710
6.

Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders.

Boilève A, Carlo MI, Barthélémy P, Oudard S, Borchiellini D, Voss MH, George S, Chevreau C, Landman-Parker J, Tabone MD, Chism DD, Amin A, Bilen MA, Bosse D, Coulomb-L'hermine A, Su X, Choueiri TK, Tannir NM, Malouf GG.

J Immunother Cancer. 2018 Dec 27;6(1):159. doi: 10.1186/s40425-018-0482-z.

7.

Integrated Multi-omic Analysis of Esthesioneuroblastomas Identifies Two Subgroups Linked to Cell Ontogeny.

Classe M, Yao H, Mouawad R, Creighton CJ, Burgess A, Allanic F, Wassef M, Leroy X, Verillaud B, Mortuaire G, Bielle F, Le Tourneau C, Kurtz JE, Khayat D, Su X, Malouf GG.

Cell Rep. 2018 Oct 16;25(3):811-821.e5. doi: 10.1016/j.celrep.2018.09.047.

8.

Metabolic Response to BRAF-MEK Combination Therapy in Cecal Neuroendocrine Carcinoma With BRAFV600E Mutation and Refractory Lactic Acidosis.

Imperiale A, Latgé A, Schaff-Wendling F, Goichot B, Kurtz JE, Malouf GG.

Clin Nucl Med. 2018 Sep;43(9):701-702. doi: 10.1097/RLU.0000000000002231.

PMID:
30036245
9.

Expression of long non-coding RNA MFI2-AS1 is a strong predictor of recurrence in sporadic localized clear-cell renal cell carcinoma.

Flippot R, Mouawad R, Spano JP, Rouprêt M, Compérat E, Bitker MO, Parra J, Vaessen C, Allanic F, Manach Q, Tannir NM, Khayat D, Su X, Malouf GG.

Sci Rep. 2017 Aug 17;7(1):8540. doi: 10.1038/s41598-017-08363-6.

10.

NSD1 Inactivation and SETD2 Mutation Drive a Convergence toward Loss of Function of H3K36 Writers in Clear Cell Renal Cell Carcinomas.

Su X, Zhang J, Mouawad R, Compérat E, Rouprêt M, Allanic F, Parra J, Bitker MO, Thompson EJ, Gowrishankar B, Houldsworth J, Weinstein JN, Tost J, Broom BM, Khayat D, Spano JP, Tannir NM, Malouf GG.

Cancer Res. 2017 Sep 15;77(18):4835-4845. doi: 10.1158/0008-5472.CAN-17-0143. Epub 2017 Jul 28.

11.

Renal Medullary Carcinoma: Establishing Standards in Practice.

Beckermann KE, Sharma D, Chaturvedi S, Msaouel P, Abboud MR, Allory Y, Bourdeaut F, Calderaro J, de Cubas AA, Derebail VK, Hong AL, Naik RP, Malouf GG, Mullen EA, Reuter VE, Roberts CWM, Walker CL, Wood CG, DeBaun MR, Van Poppel H, Tannir NM, Rathmell WK.

J Oncol Pract. 2017 Jul;13(7):414-421. doi: 10.1200/JOP.2017.020909. Review.

12.

Papillary Renal Cell Carcinoma: A Family Portrait.

Flippot R, Compérat E, Tannir NM, Malouf GG.

Eur Urol. 2018 Jan;73(1):79-80. doi: 10.1016/j.eururo.2017.06.004. Epub 2017 Jun 19. No abstract available.

PMID:
28642022
13.

Reply to 'Incidence, clinicopathological features and fusion transcript landscape of translocation renal cell carcinomas'.

Classe M, Grégoire V, Malouf GG, Leroy X.

Histopathology. 2017 Nov;71(5):836-837. doi: 10.1111/his.13290. Epub 2017 Aug 29. No abstract available.

PMID:
28640961
14.

Non-clear cell renal cell carcinomas: biological insights and therapeutic challenges and opportunities.

Malouf GG, Joseph RW, Shah AY, Tannir NM.

Clin Adv Hematol Oncol. 2017 May;15(5):409-418. Review.

PMID:
28591094
15.

Expression of human endogenous retrovirus-K is strongly associated with the basal-like breast cancer phenotype.

Johanning GL, Malouf GG, Zheng X, Esteva FJ, Weinstein JN, Wang-Johanning F, Su X.

Sci Rep. 2017 Feb 6;7:41960. doi: 10.1038/srep41960.

16.

Incidence, clinicopathological features and fusion transcript landscape of translocation renal cell carcinomas.

Classe M, Malouf GG, Su X, Yao H, Thompson EJ, Doss DJ, Grégoire V, Lenobin J, Fantoni JC, Sudour-Bonnange H, Khayat D, Aubert S, Tannir NM, Leroy X.

Histopathology. 2017 Jun;70(7):1089-1097. doi: 10.1111/his.13167. Epub 2017 Mar 21.

PMID:
28106924
17.

Repositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon Cancer Epigenome.

Raynal NJ, Da Costa EM, Lee JT, Gharibyan V, Ahmed S, Zhang H, Sato T, Malouf GG, Issa JJ.

Mol Cancer Ther. 2017 Feb;16(2):397-407. doi: 10.1158/1535-7163.MCT-16-0588. Epub 2016 Dec 15.

18.

Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study.

Shah AY, Karam JA, Malouf GG, Rao P, Lim ZD, Jonasch E, Xiao L, Gao J, Vaishampayan UN, Heng DY, Plimack ER, Guancial EA, Fung C, Lowas SR, Tamboli P, Sircar K, Matin SF, Kimryn Rathmell W, Wood CG, Tannir NM.

BJU Int. 2017 Dec;120(6):782-792. doi: 10.1111/bju.13705. Epub 2016 Dec 9.

19.

Linking Gene Mutations to Clinical Outcomes and Response to Therapy in Clear-cell Renal Cell Carcinoma: Ready for Prime Time?

Msaouel P, Malouf GG, Tannir NM.

Eur Urol. 2017 Mar;71(3):415-416. doi: 10.1016/j.eururo.2016.10.034. Epub 2016 Nov 2. No abstract available.

PMID:
27816301
20.

Modelling TFE renal cell carcinoma in mice reveals a critical role of WNT signaling.

Calcagnì A, Kors L, Verschuren E, De Cegli R, Zampelli N, Nusco E, Confalonieri S, Bertalot G, Pece S, Settembre C, Malouf GG, Leemans JC, de Heer E, Salvatore M, Peters DJ, Di Fiore PP, Ballabio A.

Elife. 2016 Sep 26;5. pii: e17047. doi: 10.7554/eLife.17047.

21.

Unique Transcriptomic Profile of Collecting Duct Carcinomas Relative to Upper Tract Urothelial Carcinomas and other Kidney Carcinomas.

Malouf GG, Compérat E, Yao H, Mouawad R, Lindner V, Rioux-Leclercq N, Verkarre V, Leroy X, Dainese L, Classe M, Descotes JL, Barthelemy P, Yacoub M, Rouprêt M, Bernhard JC, Creighton CJ, Spano JP, Su X, Khayat D.

Sci Rep. 2016 Aug 3;6:30988. doi: 10.1038/srep30988.

22.

Cancer subtypes classification using long non-coding RNA.

Flippot R, Malouf GG, Su X, Mouawad R, Spano JP, Khayat D.

Oncotarget. 2016 Aug 16;7(33):54082-54093. doi: 10.18632/oncotarget.10213. Review.

23.

A comprehensive review of genomic landscape, biomarkers and treatment sequencing in castration-resistant prostate cancer.

Seisen T, Rouprêt M, Gomez F, Malouf GG, Shariat SF, Peyronnet B, Spano JP, Cancel-Tassin G, Cussenot O.

Cancer Treat Rev. 2016 Jul;48:25-33. doi: 10.1016/j.ctrv.2016.06.005. Epub 2016 Jun 15. Review.

24.

DNA Methylation Signature Reveals Cell Ontogeny of Renal Cell Carcinomas.

Malouf GG, Su X, Zhang J, Creighton CJ, Ho TH, Lu Y, Raynal NJ, Karam JA, Tamboli P, Allanick F, Mouawad R, Spano JP, Khayat D, Wood CG, Jelinek J, Tannir NM.

Clin Cancer Res. 2016 Dec 15;22(24):6236-6246. Epub 2016 Jun 2.

25.

Therapeutic Strategies for Patients With Metastatic Renal Cell Carcinoma in Whom First-Line Vascular Endothelial Growth Factor Receptor-Directed Therapies Fail.

Malouf GG, Flippot R, Khayat D.

J Oncol Pract. 2016 May;12(5):412-20. doi: 10.1200/JOP.2016.011809. Review.

PMID:
27170687
26.

Oncogenic viruses: Lessons learned using next-generation sequencing technologies.

Flippot R, Malouf GG, Su X, Khayat D, Spano JP.

Eur J Cancer. 2016 Jul;61:61-8. doi: 10.1016/j.ejca.2016.03.086. Epub 2016 May 5. Review.

PMID:
27156225
27.

Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations.

Malouf GG, Ali SM, Wang K, Balasubramanian S, Ross JS, Miller VA, Stephens PJ, Khayat D, Pal SK, Su X, Sircar K, Tamboli P, Jonasch E, Tannir NM, Wood CG, Karam JA.

Eur Urol. 2016 Aug;70(2):348-57. doi: 10.1016/j.eururo.2016.01.051. Epub 2016 Feb 16.

PMID:
26895810
28.

Targeting Calcium Signaling Induces Epigenetic Reactivation of Tumor Suppressor Genes in Cancer.

Raynal NJ, Lee JT, Wang Y, Beaudry A, Madireddi P, Garriga J, Malouf GG, Dumont S, Dettman EJ, Gharibyan V, Ahmed S, Chung W, Childers WE, Abou-Gharbia M, Henry RA, Andrews AJ, Jelinek J, Cui Y, Baylin SB, Gill DL, Issa JP.

Cancer Res. 2016 Mar 15;76(6):1494-505. doi: 10.1158/0008-5472.CAN-14-2391. Epub 2015 Dec 30.

29.

Long non-coding RNA profiling links subgroup classification of endometrioid endometrial carcinomas with trithorax and polycomb complex aberrations.

Jiang Y, Malouf GG, Zhang J, Zheng X, Chen Y, Thompson EJ, Weinstein JN, Yuan Y, Spano JP, Broaddus R, Tannir NM, Khayat D, Lu KH, Su X.

Oncotarget. 2015 Nov 24;6(37):39865-76. doi: 10.18632/oncotarget.5399.

30.

Methylome sequencing for fibrolamellar hepatocellular carcinoma depicts distinctive features.

Malouf GG, Tahara T, Paradis V, Fabre M, Guettier C, Yamazaki J, Long H, Lu Y, Raynal NJ, Jelinek J, Mouawad R, Khayat D, Brugières L, Raymond E, Issa JP.

Epigenetics. 2015;10(9):872-81. doi: 10.1080/15592294.2015.1076955.

31.

Comprehensive analysis of long non-coding RNAs in human breast cancer clinical subtypes.

Su X, Malouf GG, Chen Y, Zhang J, Yao H, Valero V, Weinstein JN, Spano JP, Meric-Bernstam F, Khayat D, Esteva FJ.

Oncotarget. 2014 Oct 30;5(20):9864-76.

32.

Characterization of long non-coding RNA transcriptome in clear-cell renal cell carcinoma by next-generation deep sequencing.

Malouf GG, Zhang J, Yuan Y, Compérat E, Rouprêt M, Cussenot O, Chen Y, Thompson EJ, Tannir NM, Weinstein JN, Valero V, Khayat D, Spano JP, Su X.

Mol Oncol. 2015 Jan;9(1):32-43. doi: 10.1016/j.molonc.2014.07.007. Epub 2014 Jul 25.

33.

Next-generation sequencing of translocation renal cell carcinoma reveals novel RNA splicing partners and frequent mutations of chromatin-remodeling genes.

Malouf GG, Su X, Yao H, Gao J, Xiong L, He Q, Compérat E, Couturier J, Molinié V, Escudier B, Camparo P, Doss DJ, Thompson EJ, Khayat D, Wood CG, Yu W, Teh BT, Weinstein J, Tannir NM.

Clin Cancer Res. 2014 Aug 1;20(15):4129-40. doi: 10.1158/1078-0432.CCR-13-3036. Epub 2014 Jun 4.

34.

Transcriptional profiling of pure fibrolamellar hepatocellular carcinoma reveals an endocrine signature.

Malouf GG, Job S, Paradis V, Fabre M, Brugières L, Saintigny P, Vescovo L, Belghiti J, Branchereau S, Faivre S, de Reyniès A, Raymond E.

Hepatology. 2014 Jun;59(6):2228-37. doi: 10.1002/hep.27018. Epub 2014 Apr 30.

PMID:
24443104
35.

Architecture of epigenetic reprogramming following Twist1-mediated epithelial-mesenchymal transition.

Malouf GG, Taube JH, Lu Y, Roysarkar T, Panjarian S, Estecio MR, Jelinek J, Yamazaki J, Raynal NJ, Long H, Tahara T, Tinnirello A, Ramachandran P, Zhang XY, Liang S, Mani SA, Issa JP.

Genome Biol. 2013 Dec 24;14(12):R144. doi: 10.1186/gb-2013-14-12-r144.

36.

NRAS mutation is the sole recurrent somatic mutation in large congenital melanocytic nevi.

Charbel C, Fontaine RH, Malouf GG, Picard A, Kadlub N, El-Murr N, How-Kit A, Su X, Coulomb-L'Hermine A, Tost J, Mourah S, Aractingi S, Guégan S.

J Invest Dermatol. 2014 Apr;134(4):1067-1074. doi: 10.1038/jid.2013.429. Epub 2013 Oct 15.

37.

Epigenetic silencing of microRNA-203 is required for EMT and cancer stem cell properties.

Taube JH, Malouf GG, Lu E, Sphyris N, Vijay V, Ramachandran PP, Ueno KR, Gaur S, Nicoloso MS, Rossi S, Herschkowitz JI, Rosen JM, Issa JP, Calin GA, Chang JT, Mani SA.

Sci Rep. 2013;3:2687. doi: 10.1038/srep02687.

38.

Genomic heterogeneity of translocation renal cell carcinoma.

Malouf GG, Monzon FA, Couturier J, Molinié V, Escudier B, Camparo P, Su X, Yao H, Tamboli P, Lopez-Terrada D, Picken M, Garcia M, Multani AS, Pathak S, Wood CG, Tannir NM.

Clin Cancer Res. 2013 Sep 1;19(17):4673-84. doi: 10.1158/1078-0432.CCR-12-3825. Epub 2013 Jul 1.

39.

Prognostic factors and outcome of undifferentiated endometrial sarcoma treated by multimodal therapy.

Malouf GG, Lhommé C, Duvillard P, Morice P, Haie-Meder C, Pautier P.

Int J Gynaecol Obstet. 2013 Jul;122(1):57-61. doi: 10.1016/j.ijgo.2013.01.025. Epub 2013 Apr 15.

PMID:
23597861
40.

Low- and high-grade esthesioneuroblastomas display a distinct natural history and outcome.

Malouf GG, Casiraghi O, Deutsch E, Guigay J, Temam S, Bourhis J.

Eur J Cancer. 2013 Apr;49(6):1324-34. doi: 10.1016/j.ejca.2012.12.008. Epub 2013 Jan 10.

PMID:
23312882
41.

The epigenome of AML stem and progenitor cells.

Yamazaki J, Estecio MR, Lu Y, Long H, Malouf GG, Graber D, Huo Y, Ramagli L, Liang S, Kornblau SM, Jelinek J, Issa JP.

Epigenetics. 2013 Jan;8(1):92-104. doi: 10.4161/epi.23243. Epub 2012 Dec 18.

42.

Pure and mixed fibrolamellar hepatocellular carcinomas differ in natural history and prognosis after complete surgical resection.

Malouf GG, Brugières L, Le Deley MC, Faivre S, Fabre M, Paradis V, Aerts I, Le Tourneau C, Dreyer C, Branchereau S, Belghiti J, Raymond E.

Cancer. 2012 Oct 15;118(20):4981-90. doi: 10.1002/cncr.27520. Epub 2012 Mar 13.

43.

Transcription factor E3 and transcription factor EB renal cell carcinomas: clinical features, biological behavior and prognostic factors.

Malouf GG, Camparo P, Molinié V, Dedet G, Oudard S, Schleiermacher G, Theodore C, Dutcher J, Billemont B, Bompas E, Guillot A, Boccon-Gibod L, Couturier J, Escudier B.

J Urol. 2011 Jan;185(1):24-9. doi: 10.1016/j.juro.2010.08.092. Epub 2010 Nov 12.

PMID:
21074195
44.

Impact of adjuvant treatment modalities on the management of patients with stages I-II endometrial stromal sarcoma.

Malouf GG, Duclos J, Rey A, Duvillard P, Lazar V, Haie-Meder C, Balleyguier C, Morice P, Lhommé C, Pautier P.

Ann Oncol. 2010 Oct;21(10):2102-6. doi: 10.1093/annonc/mdq064. Epub 2010 Mar 19.

PMID:
20305035
45.

Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network.

Malouf GG, Camparo P, Oudard S, Schleiermacher G, Theodore C, Rustine A, Dutcher J, Billemont B, Rixe O, Bompas E, Guillot A, Boccon-Gibod L, Couturier J, Molinié V, Escudier B.

Ann Oncol. 2010 Sep;21(9):1834-8. doi: 10.1093/annonc/mdq029. Epub 2010 Feb 12.

PMID:
20154303
46.

[Molecular targeted therapies in small-cell lung cancer].

Levy A, Malouf GG, Besse B, Massard C, Soria JC.

Bull Cancer. 2010 May;97(5):535-45. doi: 10.1684/bdc.2010.1035. Review. French.

47.

Histone deacetylase inhibitors as anti-neoplastic agents.

Batty N, Malouf GG, Issa JP.

Cancer Lett. 2009 Aug 8;280(2):192-200. doi: 10.1016/j.canlet.2009.03.013. Epub 2009 Apr 3. Review.

PMID:
19345475

Supplemental Content

Loading ...
Support Center